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Abstract. Immunotherapy is a promising strategy for the 
treatment of various types of cancer. An antibody that targets 
programmed death ligand-1 (PD-L1) pathway has been shown to 
be active towards various types of cancer, including melanoma 
and lung cancer. MPDL3280A, an anti-PD-L1 antibody, has 
shown clear clinical activity in PD-L1-overexpressing bladder 
cancer with an objective response rate of 40-50%, resulting in 
a breakthrough therapy designation granted by FDA. These 
events pronounce the importance of targeting the PD-L1 
pathway in the treatment of bladder cancer. In the present study, 
we investigated the prognostic significance of the expression of 
three genes in the PD-L1 pathway, including PD-L1, B7.1 and 
PD-1, in three independent bladder cancer datasets in the Gene 
Expression Omnibus database. PD-L1, B7.1 and PD-1 were 
significantly associated with clinicopathological parameters 
indicative of a more aggressive phenotype of bladder cancer, 
such as a more advanced stage and a higher tumor grade. In 
addition, a high level expression of PD-L1 was associated with 
reduced patient survival. Of note, the combination of PD-L1 and 
B7.1 expression, but not other combinations of the three genes, 
were also able to predict patient survival. Our findings support 
the development of anti-PD-L1, which blocks PD-L1-PD-1 and 
B7.1-PD-L1 interactions, in treatment of bladder cancer. The 
observations were consistent in the three independent bladder 
cancer datasets consisting of a total of 695 human bladder 
specimens. The datasets were then assessed and it was found 
that the expression levels of the chemokine CC-motif ligand 
(CCL), CCL3, CCL8 and CCL18, were correlated with the 
PD-L1 expression level, while ADAMTS13 was differentially 
expressed in patients with a different survival status (alive or 
deceased). Additional investigations are required to elucidate 
the role of these genes in the PD-L1-mediated immune system 
suppression and bladder cancer progression. In conclusion, 
findings of this study suggested that PD-L1 is an important 
prognostic marker and a therapeutic target for bladder cancer.
Introduction
Immunotherapy has been found to be effective for bladder 
cancer, especially in non-muscle invasive diseases. Treatment 
of non-muscle invasive disease bladder cancers resulted in 
a reduction in the risk of recurrence and progression (1,2). 
Although the mechanisms for BCG in delaying recurrence 
and prolonging survival remain poorly understood (2,3), the 
modulation of the expression of a variety of cytokines and 
immune cell maturation have been demonstrated with BCG 
treatment even though their functional status and effects 
remain controversial (1).
Programmed death ligand-1 (PD-L1) is a T-cell regulatory 
molecule that may be expressed on the surface of tumor and 
tumor-infiltrating immune cells. The PD-L1/PD-1 pathway has 
been shown to be important in cancer progression (4). PD-L1 is 
frequently found to be overexpressed in tumors. By binding to 
PD-1, it may inhibit the activation of cytotoxic T lymphocytes 
in order to evade the host immune response preventing tumors 
from cytotoxic T lymphocyte-induced killing. Other than 
PD-1, PD-L1 also interacts with B7.1 to further suppress the 
tumor antigen-induced activation of cytotoxic T lymphocytes.
Tumor PD-L1 protein expression was found to be associ-
ated with a higher grade of tumors and a poorer survival rate in 
urothelial cancers (5). PD-L1 has been previously identified as 
an independent determinant for stage progression (6). Among 
other T-cell co-regulatory molecules, such as B7-H3 and PD-1, 
investigated in urothelial cell carcinoma of the bladder, only 
PD-L1 expression levels were found to be associated with an 
increased pathological stage and an independent predictor for 
all-cause mortality after cystectomy (7). Microarray tech-
nology was recently used to examine the expression of PD-L1, 
PD-1 and B7-H3 in urothelial carcinoma of the bladder (8). 
The results of that study showed that the expression levels of 
the three molecules were correlated with each other in the 
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primary tumors, while the expression of PD-L1 was associated 
with an increased risk of overall mortality in the subgroup of 
patients with organ-confined disease.
Efforts have begun to delineate the role of the PD-L1 
pathway in metastatic urothelial bladder cancer. Inhibition 
of the PD-L1 pathway by the investigational molecule, 
MPDL3280A, which blocks PD-1/PD-L1 and B7.1/PD-L1 
interactions, thereby completely inhibiting the PD-L1-
mediated immunosuppressive signals, has shown great clinical 
activity (9). Patients whose urothelial bladder tumors or their 
associated tumor-infiltrating lymphocytes had PD-L1 expres-
sion of an immunohistochemical (IHC) score of 2+ or 3+ had 
an objective response rate of 40 and 50%, respectively (9). 
Those results led to a breakthrough therapy designation status 
for MPDL3280A in the treatment of metastatic urothelial 
bladder cancer granted by FDA in the uSA, indicating that 
PD-L1 is an important target that should be investigated.
Although IHC is a standard test for protein overexpression, 
the resulting interpretation is often solely visual and highly 
subjective. For instance, diagnosis of the HER2 overexpression 
levels in breast cancer often requires complementary fluores-
cence in situ hybridization analysis for those patients with 
an IHC staining score of 2+, due to the difficulty of defining 
a true-positive result, when the staining itself is moderate. 
Assessment of gene expression at the transcriptional level by 
quantitative tests removes the subjectivity of interpreting IHC 
results. In the present study, we aimed to analyze the mRNA 
expression of related molecules of the PD-L1 pathway and the 
prognostic significance of the players in the PD-L1 pathway in 
early bladder cancer, by investigating the associations of the 
expression of PD-L1, B7.1 and PD-1 and the clinicopatholog-
ical parameters in three bladder cancer patient cohorts using 
available microarray and patient data.
Materials and methods
Extraction of clinical and microarray gene expression 
data from bladder cancer patient datasets. Three bladder 
cancer patient datasets, GSE13507 (n=256) (10), GSE32894 
(n=308) (11) and GSE32548 (n=131) (12) were identified from 
the Gene Expression Omnibus database based on the following 
search criteria: i) bladder or urothelial cancer, ii) available 
information on clinicopathological parameters, iii) available 
information on the PD-L1, B7.1 and PD-1 gene expression 
levels and iv) with a sample size of ≥100. The GEO website 
has standardized uRLs for its individual datasets, such as 
the overall summary information regarding the microarray 
dataset GSE13507 accessed at http://www.ncbi.nlm.gov/geo/
query/acc.cgi?acc=GSE13507. For each GEO data series, 
links are provided at the bottom of the page to the Series 
Matrix File(s), which contain the expression values for each 
gene (probe set) and each microarray. The uRLs to the Series 
Matrix File(s) are also standardized. For GSE13507, the uRL 
was ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/SeriesMatrix/
GSE13507. The files in gzip format were then unzipped to the 
tab-delimited text format, which contained detailed informa-
tion for statistical analysis. R scripting was used to extract the 
expression values of a small number of genes (probe sets) of 
interest and the clinical data from the data matrices down-
loaded from GEO.
Correlations of gene expression levels and clinical data. 
The statistical analyses were performed using SPSS19.0. 
The associations between the expression levels of the genes 
were analyzed by the Spearman's rank test. The expression 
levels were then divided into high and low levels using the 
higher quartile expression level as the cut-off point for the 
Kaplan-Meier survival analysis. The results were compared 
by the log-rank test. The patients were divided into three 
groups based on the expression levels of PD-L1 and B7.1. 
The PD-L1/B7.1 low group comprised patients expressing the 
two genes at low levels, the PD-L1/B7.1 intermediate group 
comprising patients expressing one of the two genes at high 
levels, and the PD-L1/B7.1 high group comprising patients 
expressing the two genes at high levels. The survival time of 
the patients stratified by this grouping method was analyzed 
by the Kaplan-Meier survival analysis as described above. 
The univariate Cox regression and multivariate analyses were 
performed for the clinicopathological parameters, including 
gender, age, T-stage, tumor type and grade and PD-L1 expres-
sion. The multivariate Cox regression analysis with forward 
stepwise selection and an entry limit of p<0.05 was performed 
to identify independent predictors of survival in the patient 
cohort. Muscle invasive bladder cancer specimens were exam-
ined using the Chi-square test.
Identification of PD-L1 co-expressing genes. The patients 
were stratified into two groups based on the expression levels 
of PD-L1 as described above. The gene expression patterns of 
patients in the PD-L1 low subgroup and those in the PD-L1 
high subgroup (whose survival was significantly poorer) 
were compared. Probe sets that were differentially expressed 
between the two subgroups were identified by the two-sample 
welch's t-test. This test was used to avoid the type I error due to 
unequal variances of the values of the probe sets between the 
subgroups. Briefly, a Welch's t-test was applied to each probe 
set corresponding to a certain gene in the data matrix using 
our own Java application MyStats. P-values and the differential 
expression in fold-changes for all the probe sets were generated 
as tab-delimited worksheets of Excel for subsequent analysis.
Identification of therapeutic targets for bladder cancer patients 
overexpressing PD-L1. Patients who had tumors expressing a 
high level of PD-L1 were stratified into two groups based on 
their survival status (alive or deceased). Differential expres-
sion of different probe sets between patients in the PD-L1 
high-alive subgroup and those in the PD-L1 high-deceased 
subgroup were identified as described above.
Results
Association between the expression levels of PD-L1, B7.1 and 
PD-1 with clinicopathological parameters and survival in 
bladder cancer. Three independent microarray datasets were 
identified in the GEO database when we limited our search 
to include only bladder cancer datasets with a sample size of 
>100 patients and available clinical data, including survival 
and tumor grade. The three datasets were GSE13507 (n=256), 
GSE32894 (n=308) and GSE32548 (n=131). The expression 
levels of PD-L1, B7.1 and PD-1 were extracted and correlated 
with available clinical data for the three datasets.
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In GSE13507 (n=256) (10), PD-L1 and B7.1 expression 
did not vary significantly between normal bladder (n=10), 
surrounding mucosa (n=58), bladder cancer (n=165) and 
recurrent tumor (n=23), while the expression of PD-1 was 
significantly reduced in bladder cancer compared to normal 
bladder or surrounding mucosa (welch's t-test, p<0.001; 
post-hoc Games-Howell test, p=0.024 and p=0.001, respec-
tively). Muscle invasive bladder cancer specimens expressed 
significantly more PD-L1 (Fig. 1A; Chi-square test, p<0.001) 
and B7.1 (data not shown). The expression levels of PD-L1 were 
significantly higher with a higher T stage (Fig. 1B; Chi-square 
test, p<0.001) and were also significantly higher with a higher 
N stage of the tumors (Fig. 1C; Chi-square test, p<0.001). The 
expression levels of the three genes were significantly higher in 
tumors of high grade than those of low grade (data not shown). 
In addition, the mRNA expression of PD-L1 was significantly 
higher (welch's t-test, p=0.039) in primary tumors with M1 
(n=7) stage than those with M0 stage (n=158), although the 
number of specimens with M1 stage was small (Fig. 1D). 
we also investigated whether PD-L1 expression was associ-
ated with patient survival by stratifying the cohort into two 
sub-cohorts based on their PD-L1 expression. One sub-cohort 
comprised the quartile of patients with the highest PD-L1 
expression, and the second sub-cohort that of the remaining 
three quartiles. Notably, the high expression of PD-L1 mRNA 
(top 25%) in the primary tumors was significantly associ-
ated with a reduced overall survival time (Fig. 1E; log-rank 
test, p<0.001) and a shorter disease-specific survival time of 
patients (log-rank test, p<0.001). No significant association 
was observed for the expression of B7.1 or PD-1.
In GSE32894 (n=308) (11), we found that the expression 
level of PD-L1 was significantly higher in tumors of higher 
stage (Fig. 2A, p<0.001) and grade (Fig. 2B, p=0.005). The 
expression levels of B7.1 and PD-1 were also significantly 
Figure 1. The association between PD-L1 expression and clinicopathological parameters in GSE13507 cohorts with 165 bladder cancer specimens. Histograms 
showing the percentage of cases with different PD-L1 expression according to (A) the muscle invasive status of the tumors, (B) the T stage of the tumors, 
(C) the N stage of the tumors, and (D) the M stage of the tumors. Kaplan-Meier plots for disease-specific survival for patients with (E) differential PD-L1 
expression, and (F) for overall survival for patients with differential PD-L1 expression. PD-L1, programmed death ligand-1.
HuANG et al:  PD-L1 IN BLADDER CANCER3078
higher in tumors of a higher stage and grade (data not shown). 
The mRNA expression of PD-L1 (Fig. 2C, p<0.001) and B7.1 
(data not shown), but not that of PD-1 (data not shown), was 
significantly higher in subtype MS2b2.2, which is one of 
the two subtypes with a poorer prognosis compared to the 
remaining five subtypes (11). Similar to the other datasets, a 
high level of PD-L1 (top 25%) expression was significantly 
associated with a shorter overall survival time (Fig. 2D; log-
rank test, p=0.033). Again, this association was not observed 
for B7.1 or PD-1 expression.
Figure 2. The association between PD-L1 expression and clinicopathological parameters in GSE32894 cohorts with 308 bladder cancer specimens. Histograms 
showing (A) the percentage of cases with a different PD-L1 expression according to the T-stage of the tumors, (B) the percentage of the cases with different 
PD-L1 expression according to the histological grading of the tumors, and (C) the percentage of cases with different PD-L1 expression according to the 
molecular subtype of the tumors. (D) Kaplan-Meier analysis for overall survival for patients with differential PD-L1 expression. PD-L1, programmed death 
ligand-1.
Figure 3. The association between PD-L1 expression and the clinicopathological parameters in GSE32548 cohorts with 131 bladder cancer specimens. Error 
bar plots for the PD-L1 expression in tumors with a different (A) T stage, and (B) histological grading. PD-L1, programmed death ligand-1.
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In GSE32548 (n=131) (12), the PD-L1 mRNA expres-
sion level was significantly higher in patients with a higher 
T-stage (Fig. 3A, p=0.012) and tumor grade (Fig. 3B, p=0.014). 
The same was true for B7.1 and PD-1, the expression of which 
was enhanced with the increasing T-stage and tumor grade 
(data not shown).
The results suggested that a high level of the PD-L1 expres-
sion predicts a poor prognosis of bladder cancer patients in 
terms of patient survival. while an association between the 
B7.1 expression and the survival of bladder cancer patients was 
not demonstrated, its high level of expression was associated 
significantly with tumors with more aggressive phenotypes.
Correlations between the expression of PD-L1, B7.1 and PD-1. 
The correlations of the mRNA expression of the three genes 
were then studied to determine whether they are co-over-
expressed in bladder cancer. The three genes were highly 
correlated with each other in the radical cystectomy specimens 
in the three datasets analyzed (Fig. 4). In GSE13507 (n=256), 
the expression of PD-L1 was significantly positively correlated 
with that of B7.1 and PD-1 (Fig. 4A and D; Spearman's rank 
test, r=0.233, p<0.001; and r=0.194, p=0.002, respectively), 
while the B7.1 expression also significantly positively corre-
lated with the PD-1 expression (data not shown). In GSE32894 
(n=308), the expression of PD-L1 was significantly posi-
Figure 4. The correlation between PD-L1 and B7.1, and between PD-L1 and PD-1 in the three bladder cancer datasets. Scatter plots showing the expres-
sion of PD-L1 vs. B7.1 in (A) GSE13507, (B) GSE32894 and (C) GSE32548, and the expression of PD-L1 vs. PD-1 in (D) GSE13507, (E) GSE32894 and 
(F) GSE32548. PD-L1, programmed death ligand-1.
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tively correlated with that of B7.1 and PD-1 (Fig. 4B and E; 
Spearman's rank test, r=0.317, p<0.001; and r=0.268, p<0.001, 
respectively), while the B7.1 expression was also signifi-
cantly positively correlated with the PD-1 expression (data 
not shown). In GSE32548 (n=131), the expression of PD-L1 
was significantly positively correlated with that of B7.1 and 
PD-1 (Fig. 4C and F; Spearman's rank test, r=0.456, p<0.001; 
and r=0.285, p=0.001, respectively), while the B7.1 expression 
was also significantly positively correlated with the PD-1 
expression (data not shown). These results suggested that the 
mRNA expression of PD-L1 is highly correlated with that of 
B7.1 and PD-1.
Association of co-overexpression of PD-L1 and B7.1, and 
survival in bladder cancer. we investigated whether the 
correlations between PD-L1 and B7.1, and between PD-L1 and 
PD-1 may be of prognostic significance. Patients expressing 
high levels of PD-L1 and B7.1 had a shorter survival time 
than those patients expressing low levels of PD-L1 and B7.1 
(Fig. 5). In GSE13507, patients with bladder cancer expressing 
high levels of PD-L1 and B7.1 had a mean overall survival 
of 62 months compared to 115 months for those with bladder 
cancer expressing low levels of PD-L1 and B7.1 (Fig. 5A; log-
rank test, p=0.001). Similarly, patients with bladder cancer 
expressing high levels of the two genes had a mean disease-free 
survival of only 56 months, which was significantly shorter than 
89 months for those patients with bladder cancer expressing 
low levels of the two genes (Fig. 5B; log-rank test, p=0.012). In 
addition, similar results were obtained in GSE32894. Patients 
with bladder cancer expressing high level of the two genes had 
a mean survival of 79 months, which was significantly shorter 
than 100 months for those patients with their bladder cancers 
expressing low levels of the two genes (Fig. 5C; log-rank test, 
p=0.021). However, no significant association was detected for 
the co-expression of PD-L1 and PD-1 or that of B7.1 and PD-1. 
These results suggested that the co-overexpression of PD-L1 
and B7.1, but not that of the other combinations, is important 
for bladder cancer progression.
PD-L1 expression is an independent predictor for survival 
in bladder cancer. Since the PD-L1 expression was the most 
significant factor among PD-L1, PD-1 and B7.1, in predicting 
survival in bladder cancer, we investigated whether the asso-
ciation between PD-L1 expression and survival is independent 
of other predictive clinicopathological parameters. Since the 
GSE13507 dataset had a high sample number as well as a high 
event rate, this dataset was optimal for identifying independent 
predictive factors. As shown in Tables I and II, using multivar-
iate Cox regression analysis, PD-L1 expression, T stage, tumor 
type and age were independent predictors for disease-specific 
survival, while for PD-L1 expression, T stage and age were 
independent predictors for overall survival, respectively. This 
analysis suggested that the PD-L1 expression is an important 
prognostic factor in bladder cancer independent of the T stage 
as well as whether it is muscle invasive or not.
Identification of PD-L1 co-regulated genes in bladder cancer. 
we investigated the differential gene expression between 
Figure 5. The association between the combination of PD-L1 and B7.1 expression and bladder cancer survival. Kaplan-Meier plots for (A) disease-free survival, 
(B) overall survival in the GSE13507 cohort, and (C) overall survival in the GSE32894 cohort, of patients with different PD-L1 and B7.1 expression. PD-L1, 
programmed death ligand-1.
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bladder cancer expressing a high level of PD-L1 and those 
expressing a low level of PD-L1. Of the genes that were 
correlated with PD-L1 expression in bladder cancer, three 
chemokine (C-C motif) ligand (CCL) genes, CCL3, CCL8 and 
CCL18, were among the top 30 differentially expressed genes 
with some of the lowest p-values found during the comparison. 
Table I. Cox regression analysis of disease-specific survival in GSE13507 bladder cancer dataset.
 univariate analysis  Multivariate analysis
 ---------------------------------------------------------------------------- ------------------------------------------------------------------------------
Clinicopathological variables Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Gender
  Female (n=30) 1 Reference
  Male (n=135) 0.477 (0.220-1.032) 0.060
Age (years) (n=165) 1.051 (1.016-1.088) 0.004 1.061 (1.020-1.096) 0.001
T stage
  Early (n=135) 1 Reference 1 Reference
  Advanced (n=30) 12.747 (6.129-26.509) <0.001 3.261 (1.464-7.267) 0.004
Tumor type
  Non-muscle invasive (n=103) 1 Reference 1 Reference
  Muscle invasive (n=62) 24.719 (7.501-81.457) <0.001 13.342 (3.556-50.065) <0.001
Grade
  Low (n=105) 1 Reference
  High (n=60) 5.980 (2.755-12.980) <0.001
PD-L1 expression
  Low (n=125) 1 Reference 1 Reference
  High (n=40) 4.049 (2.020-8.117) <0.001 2.972 (1.442-6.127) 0.003
PD-L1, programmed death ligand-1. Numbers in bold indicate statistical significance (p<0.05).
Table II. Cox regression analysis of overall survival in GSE13507 bladder cancer dataset.
 univariate analysis Multivariate analysis
 ---------------------------------------------------------------------------- --------------------------------------------------------------------------------
Clinicopathological variables Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Gender
  Female (n=30) 1 Reference
  Male (n=135) 0.641 (0.361-1.138) 0.129
Age (years) (n=165) 1.070 (1.044-1.096) <0.001 1.066 (1.039-1.093) <0.001
T stage
  Early (n=135) 1 Reference 1 Reference
  Advanced (n=30) 4.400 (2.611-7.414) <0.001 4.576 (2.668-7.846) <0.001
Tumor type
  Non-muscle invasive (n=103) 1 Reference
  Muscle invasive (n=62) 2.897 (1.791-4.684) <0.001
Grade
  Low (n=105) 1 Reference
  High (n=60) 2.740 (1.694-4.433) <0.001
PD-L1 expression
  Low (n=125) 1 Reference 1 Reference
  High (n=40) 3.025 (1.850-4.946) <0.001 2.273 (1.370-3.771) 0.001
PD-L1, programmed death ligand-1. Numbers in bold indicate statistical significance (p<0.05).
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Since CCLs have been suggested to play an important role 
in malignant growth and metastasis (13), the correlations 
between PD-L1 expression and the CCL3, CCL8 and CCL18 
expression levels were investigated by the Spearman's rank 
test. In GSE13507, PD-L1 expression was significantly posi-
tively correlated with the CCL3 (Fig. 6A; r=0.307, p<0.001), 
CCL8 (Fig. 6D; r=0.284, p<0.001) and CCL18 (Fig. 6G; 
r=0.316, p<0.001) expression levels. In GSE32894, PD-L1 
expression was significantly positively correlated with 
CCL3 (Fig. 6B; r=0.375, p<0.001), CCL8 (Fig. 6E; r=0.420, 
p<0.001) and CCL18 (Fig. 6H; r=0.245, p<0.001) expression 
levels. In GSE32548, PD-L1 expression was significantly 
positively correlated with CCL3 (Fig. 6C; r=0.344, p<0.001), 
CCL8 (Fig. 6F; r=0.364, p<0.001) and CCL18 (Fig. 6I; 
r=0.226, p=0.009) expression levels.
Identification of genes that predict survival in patients with 
high level expression of PD-L1. we investigated differentially 
expressed genes in patients with a high level of PD-L1 between 
those who were still alive and those who were deceased at the 
last follow-up. Patient survival data were available in two of 
the datasets in the present study. Only the ADAMTS13 expres-
sion was shown to confer further prognostic value in those 
patients with bladder cancer already expressing a high level of 
PD-L1, consistently, in the two datasets with the survival time 
available. A lower median expression of the ADAMTS13 gene 
was significantly associated with a shorter overall survival 
time in the GSE13507 (Fig. 7B; log-rank test, p=0.003) and 
GSE32894 (Fig. 7D; log-rank test, p=0.006) datasets only in 
patients whose bladder cancer expressed a high level of PD-L1, 
but not in the other patients (Fig. 7B and D).
Figure 6. The correlation between PD-L1 and CCLs in the three bladder cancer datasets. Scatter plots showing the expression of PD-L1 vs. CCL3 in 
(A) GSE13507, (B) GSE32894 and (C) GSE32548, the expression of PD-L1 vs. CCL8 in (D) GSE13507, (E) GSE32894 and (F) GSE32548, and he expression 
of PD-L1 vs. CCL18 in (G) GSE13507, (H) GSE32894 and (I) GSE32548. PD-L1, programmed death ligand-1; CCL, chemokine CC-motif ligand.
ONCOLOGY REPORTS  33:  3075-3084,  2015 3083
Discussion
The PD-L1 pathway is important in cancer immuno-
surveillance  (14), and is an important target for cancer 
immunotherapy (15). MPDL3280A, a monoclonal antibody 
targeting PD-L1, has shown promising response in the treat-
ment of bladder cancer in a phase I study (9). In the present 
study, we have shown that the expression of PD-L1, B7.1 and 
PD-1 was associated with more aggressive clinicopathological 
parameters of bladder cancer in three independent cancer 
datasets, a highly consistent observation. Additionally, a high 
level of expression of PD-L1, but not that of B7.1 and PD-1, 
was associated with a shorter survival time in two independent 
bladder cancer datasets, suggesting that PD-L1 is a potential 
prognostic factor and a promising therapeutic target in bladder 
cancer.
The expressions of PD-L1, B7.1 and PD-1 were significantly 
correlated with each other. Thus, we investigated the prognostic 
significance of their entwining relationships. Only the PD-L1 
and B7.1 co-overexpression was significantly associated with 
a shorter survival time in bladder cancer patients. The latter 
finding is important, as there is an important difference 
between the antibody targeting PD-L1 and PD-1, i.e., while 
the anti-PD-L1 antibody may be able to block the PD-L1-PD-1 
and PD-L1-B7.1 interactions, the anti-PD-1 antibody would 
be ineffective against the PD-L1-B7.1 interaction (9,16), thus 
rationalizing the use of an anti-PD-L1 antibody, MPDL3280A, 
in clinical trials for the treatment of bladder cancer.
CCL3 has been shown to be produced by myeloid cells 
from bladder cancer patients, while expansion of these myeloid 
cells is associated with cancer-related inflammation and 
tumor-induced immune suppression (17). The urinary concen-
tration of CCL18 has been shown to be significantly elevated 
in bladder cancer patients and a highly specific biomarker for 
the early detection of bladder cancer (18,19). Since CCL18 
expression is mainly detected in inflammatory cells in bladder 
tumor specimens (20), it follows that a high level of expression 
of CCLs in bladder cancer specimens may reflect the amount 
of tumor infiltrating lymphocytes. Tumor-infiltrating lympho-
cytes are an important phenomenon implicating activation of 
the immune system for the killing of tumor cells, which has 
been shown to correlate with patient survival (21). However, 
the overexpression of PD-L1 has been shown to be common in 
tumor cells and infiltrating lymphocytes, and this suppresses 
the activation of these immune cells and their ability to kill 
tumor cells (4,22). In the present study, we have shown that the 
expression of PD-L1 in bladder cancer specimens was signifi-
cantly positively correlated with the expression of CCLs, and 
we hypothesize that PD-L1 expression in tumor specimens 
may be associated with increased tumor-infiltrating lympho-
cytes, although due to the high level of expression of PD-L1, 
patients would still possess poorer prognosis.
ADAMTS13 is a metalloprotease that is crucial in the 
prevention of spontaneous microvascular thrombosis (23). 
ADAMTS13 has been found to play a role in the regula-
tion of leukocyte adhesion and extravasation during 
Figure 7. The association between ADAMTS13 expression and bladder cancer survival in patients with different PD-L1 expression Kaplan-Meier plots for 
overall survival for the differential expression of ADAMTS13 in patients with a (A) low or (B) high level of expression of PD-L1 in the GSE13507 patient 
cohort, and in patients with a (C) low or (D) high level of expression of PD-L1 in the GSE32894 patient cohort. PD-L1, programmed death ligand-1.
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inf lammation (23,24). Tumor-associated inflammation 
may induce the expression of various molecules in tumor 
sites and create a microenvironment that promotes cancer 
development (25). Since our data suggest that expression of 
ADAMTS13 confers further prognostic value to PD-L1 high 
bladder cancer, we find it possible that ADAMTS13-modulated 
inflammation may impair PD-L1-mediated cancer immuno-
surveillance. Future studies may be useful to determine the 
interrelationship of ADAMTS13 and PD-L1 in the progression 
of bladder cancer.
In conclusion, our data suggest that PD-L1 plays an impor-
tant role in bladder cancer progression, and that PD-L1 is a 
promising therapeutic target for bladder cancer.
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